S&P 500   4,582.22 (+1.09%)
DOW   35,343.66 (+0.90%)
QQQ   372.53 (+1.65%)
AAPL   169.13 (+1.74%)
MSFT   310.18 (+2.26%)
FB   324.62 (+1.57%)
GOOGL   2,739.64 (+1.38%)
AMZN   3,129.79 (+0.12%)
TSLA   1,035.78 (+4.03%)
NVDA   254.05 (+1.35%)
BABA   133.56 (+4.56%)
NIO   30.43 (+6.29%)
AMD   127.70 (-0.44%)
CGC   7.98 (+4.45%)
MU   89.37 (-0.70%)
GE   100.91 (+0.29%)
T   27.37 (+0.33%)
F   22.32 (-0.58%)
DIS   151.13 (+0.68%)
AMC   19.17 (+4.64%)
PFE   54.14 (+1.12%)
ACB   5.03 (+3.50%)
BA   220.41 (+1.53%)
S&P 500   4,582.22 (+1.09%)
DOW   35,343.66 (+0.90%)
QQQ   372.53 (+1.65%)
AAPL   169.13 (+1.74%)
MSFT   310.18 (+2.26%)
FB   324.62 (+1.57%)
GOOGL   2,739.64 (+1.38%)
AMZN   3,129.79 (+0.12%)
TSLA   1,035.78 (+4.03%)
NVDA   254.05 (+1.35%)
BABA   133.56 (+4.56%)
NIO   30.43 (+6.29%)
AMD   127.70 (-0.44%)
CGC   7.98 (+4.45%)
MU   89.37 (-0.70%)
GE   100.91 (+0.29%)
T   27.37 (+0.33%)
F   22.32 (-0.58%)
DIS   151.13 (+0.68%)
AMC   19.17 (+4.64%)
PFE   54.14 (+1.12%)
ACB   5.03 (+3.50%)
BA   220.41 (+1.53%)
S&P 500   4,582.22 (+1.09%)
DOW   35,343.66 (+0.90%)
QQQ   372.53 (+1.65%)
AAPL   169.13 (+1.74%)
MSFT   310.18 (+2.26%)
FB   324.62 (+1.57%)
GOOGL   2,739.64 (+1.38%)
AMZN   3,129.79 (+0.12%)
TSLA   1,035.78 (+4.03%)
NVDA   254.05 (+1.35%)
BABA   133.56 (+4.56%)
NIO   30.43 (+6.29%)
AMD   127.70 (-0.44%)
CGC   7.98 (+4.45%)
MU   89.37 (-0.70%)
GE   100.91 (+0.29%)
T   27.37 (+0.33%)
F   22.32 (-0.58%)
DIS   151.13 (+0.68%)
AMC   19.17 (+4.64%)
PFE   54.14 (+1.12%)
ACB   5.03 (+3.50%)
BA   220.41 (+1.53%)
S&P 500   4,582.22 (+1.09%)
DOW   35,343.66 (+0.90%)
QQQ   372.53 (+1.65%)
AAPL   169.13 (+1.74%)
MSFT   310.18 (+2.26%)
FB   324.62 (+1.57%)
GOOGL   2,739.64 (+1.38%)
AMZN   3,129.79 (+0.12%)
TSLA   1,035.78 (+4.03%)
NVDA   254.05 (+1.35%)
BABA   133.56 (+4.56%)
NIO   30.43 (+6.29%)
AMD   127.70 (-0.44%)
CGC   7.98 (+4.45%)
MU   89.37 (-0.70%)
GE   100.91 (+0.29%)
T   27.37 (+0.33%)
F   22.32 (-0.58%)
DIS   151.13 (+0.68%)
AMC   19.17 (+4.64%)
PFE   54.14 (+1.12%)
ACB   5.03 (+3.50%)
BA   220.41 (+1.53%)
NASDAQ:CNTX

Context Therapeutics News Headlines

$2.10
+0.03 (+1.45%)
(As of 01/20/2022 12:30 PM ET)
Add
Compare
Today's Range
$2.00
$2.13
50-Day Range
$2.07
$7.16
52-Week Range
$2.06
$10.87
Volume
4,176 shs
Average Volume
1.33 million shs
Market Capitalization
$23.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Get Context Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Context Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CNTX
News Sentiment

0.03

0.33

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CNTX Articles
This Week

1

1

CNTX Articles
Average Week



Context Therapeutics (NASDAQ:CNTX) News Headlines Today

SourceHeadline
nasdaq.com logoContext Therapeutics Inc Shares Fall 2.2% Below Previous 52-Week Low - Market Mover
nasdaq.com - January 15 at 3:25 AM
MarketBeat logoContext Therapeutics (NASDAQ:CNTX) Trading Up 5%
americanbankingnews.com - January 12 at 2:22 AM
proactiveinvestors.com logoContext Therapeutics adds two new executives to strengthen its research and development team
proactiveinvestors.com - January 5 at 9:37 PM
finance.yahoo.com logoContext Therapeutics® Strengthens Research & Development Team
finance.yahoo.com - January 5 at 4:37 PM
finance.yahoo.com logoIntegral Molecular Adds Transgenic Humanized Mice to Expand its MPS Antibody Discovery Platform Through a Partnership with Alloy Therapeutics
finance.yahoo.com - January 5 at 11:37 AM
finance.yahoo.com logoContext Therapeutics® to Participate in Two January 2022 Investor Conferences
finance.yahoo.com - January 4 at 12:43 PM
bizjournals.com logo2021 in Review: 5 local life sciences companies bring in more than $400M combined from IPOs
bizjournals.com - December 20 at 11:28 PM
proactiveinvestors.com logoContext Therapeutics announces positive data from Onapristone extended release in early breast cancer
proactiveinvestors.com - December 10 at 10:24 AM
proactiveinvestors.com logoContext Therapeutics says its ONA-XR therapy shows positive data in early breast cancer
proactiveinvestors.com - December 10 at 10:24 AM
baystreet.ca logoContext Gains on New Information
baystreet.ca - December 10 at 10:24 AM
finance.yahoo.com logoContext Therapeutics Shares Surge On Encouraging Data From Onapristone In Early Breast Cancer
finance.yahoo.com - December 10 at 10:23 AM
finance.yahoo.com logoContext Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium
finance.yahoo.com - December 9 at 6:31 PM
bizjournals.com logoContext Therapeutics raises $31M in fresh funding from stock sale
bizjournals.com - December 7 at 1:22 PM
proactiveinvestors.com logoContext Therapeutics closes its $31.3M private placement
proactiveinvestors.com - December 7 at 1:22 PM
proactiveinvestors.com logoContext Therapeutics talks through 'pivotal' 3Q including recent $31.25M PIPE investment
proactiveinvestors.com - December 3 at 5:53 PM
proactiveinvestors.com logoContext Therapeutics reports 3Q results during a “pivotal” period for the company
proactiveinvestors.com - December 3 at 12:53 PM
finance.yahoo.com logoContext Therapeutics® Reports Third Quarter 2021 Operating and Financial Results
finance.yahoo.com - December 2 at 8:34 PM
msn.com logoContext Therapeutics Shares Drop After Raising $31M Via Equity
msn.com - December 2 at 10:24 AM
finance.yahoo.com logoContext Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium
finance.yahoo.com - November 19 at 12:17 PM
proactiveinvestors.com logoContext Therapeutics on track to report initial data from its four women's cancer focused clinical trials in 2022
proactiveinvestors.com - November 10 at 8:21 PM
finance.yahoo.com logoContext Therapeutics® and Wisconsin Oncology Network Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Metastatic Breast Cancer
finance.yahoo.com - November 1 at 8:24 AM
Get Context Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.